The rise of Viagra and its impact on the drug landscape presents a intricate question for traders. While the early sales figures were astounding, the intellectual property has lapsed, leading to a flood of off-brand alternatives that are chipping away at revenue. Moreover, the sector is facing difficulties related to demographic trends and shifting